Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
This observational study will characterize the diagnostic and therapeutic management of autoimmune cytopenias including autoimmune hemolytic anemia, immune thrombocytopenia, and chronic idiopathic/autoimmune neutropenia to evaluate predictors of outcome. Additionally, a subgroup of patients with myelodysplastic syndromes (diagnosed according to current WHO 5th edition 2022) will be included to evaluate the presence of autoimmune activation, and red cell metabolism.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of autoimmune cytopenias (AIHA/ITP/CIN/AIN)
age \>/= 18 years
ability to sign informed consent
availability to undergo 3 year follow up
for the subgroup of patients with myelodysplastic syndrome: bone marrow evaluation showing \>/= 10% dysplastic features of at least one lineage along with MDS defining cytopenia and/or MDS defining cytogenetics.
You may not be if
any condition impeding the acquisition of the informed consent
immune cytopenia diagnosis preceding \>/= 6 months the enrolment